Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics Inc. (NASDAQ:PLYX) shares are up on Tuesday as the company has made significant strides in advancing its clinical programs.
The positive movement follows the announcement that Polaryx has selected a contract research organization for its SOTERIA Phase 2 basket trial, which aims to evaluate its lead candidate, PLX-200, across multiple lysosomal storage disorders.
The SOTERIA trial represents a flexible and resource-efficient mechanism for the clinical development of PLX-200.
Polaryx’s selection of a leading contract research organization marks a pivotal milestone as it prepares to initiate the SOTERIA trial in the first half of 2026. The trial is designed to assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders, with the company having received a safe to proceed letter from the FDA in October 2025.
The SOTERIA trial will incorporate analyses comparing natural history data as a control arm to the treated arm of PLX-200, which is an orally available compound derived from gemfibrozil. This trial is expected to gather crucial data that will inform the future clinical development pathway for PLX-200, potentially leading to conditional marketing authorization if compelling clinical activity is demonstrated.
PLYX Price Action: Polaryx Therapeutics shares were up 46.06% at $3.52 at the time of publication on Tuesday. The stock is trading near its 52-week low of $2.20.
Photo: jittawit21/Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SpaceX (SPCX.US) Starship reaches orbit for the first time, Wall Street unanimously bullish: Computing power leasing behind the scenes opens up valuation imagination
Wall Street's bullish outlook is not based on Starship, but on "computing power surpassing Starlink": SpaceX's computing power business is expected to overtake Starlink as early as the first quarter of 2027.
Bitmine Immersion stock slides 2.61% to $26.84 as daily uptrend stays intact
US-Iran Talks Affect Market, Nasdaq Futures Turn Higher, US Treasury Yields Fluctuate at High Levels, Gold and Oil Both Rise
The MSCI Global Index fell by 0.2%, hitting a new low since September 18. Nasdaq futures turned positive after previously dropping 0.5%. The yield on 10-year US Treasury bonds rose by 1 basis point to 5.25% after reaching its highest level since 2007 on Monday. Brent crude rose 1.2% to $99; spot gold gained 0.7% to $4,145 per ounce.
Crypto prices
More
